Neumora Therapeutics, Inc.

Stock Chart, Company Information, and Scan Results

$1.51(as of Jun 18, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Neumora Therapeutics, Inc. Company Information, Fundamentals, and Technical Indicators

Stock Price$1.51
Ticker SymbolNMRA
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees92
CountyUSA
Market Cap$279.8M
EBIDTA-218.0M
10-Day Moving Average1.56
P/E Ratio-1.22
20-Day Moving Average1.69
Forward P/E Ratio0.00
50-Day Moving Average1.93
Earnings per Share-1.33
200-Day Moving Average2.19
Profit Margin-Infinity%
RSI44.04
Shares Outstanding185.3M
ATR0.23
52-Week High3.65
Volume2,200,600
52-Week Low0.72
Most Recent Support Level0.83
Book Value70.7M
Most Recent Resistance Level1.59
P/B Ratio3.84
Upper Keltner2.20
P/S RatioInfinity
Lower Keltner1.18
Debt-to-Equity Ratio2.20
Next Earnings Date08/03/2026
Cash Surplus117.0M
Next Ex-Dividend DateUnknown

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Neumora Therapeutics, Inc. In Our Stock Scanner

As of Jun 18, 2026
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.